OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments. Source: OpenAI Blog · Summarized by HeadlinesBriefing Related articlesTuchel frustrated by 'freestyling' as NZ boss says England 'need to be better'Saudis Aided Family of Engineer Accused of Bugging OpenAI, Prosecutors SayBotched final play sees Luka hesitate, LeBron missAccused OpenAI spy had folder called “Saudi Gov Docs,” FBI saysEngland booed off after limp Japan defeatMore from OpenAI BlogFranchisee reconciles cash in 94% less time with ChatGPT WorkAdvancing coding in low‑resource programming languagesHow Itaú is building generative AI for its entire customer baseStack Overflow for Agents triples signups with ChatGPT pluginBenefit Street Partners answers questions faster with CodexLatest in DeveloperSimCity, but with Permits · Hacker NewsAdvanced coding in low-resource programming languages · Hacker NewsGoogle open-sources TorchTPU, a native PyTorch back end for TPUs · Hacker NewsVoxtral 3 · Hacker NewsSixteen Years After Deepwater Horizon, Deep Sea Life Shows Few Signs of Recovery · Hacker NewsRelated briefingsDeveloper & AI 24-Hour BriefingDeveloper & AI 8-Hour BriefingHomeDeveloperOpenAI acquires Orchestra BioSectionsHomePublic MarketsPrivate MarketsTech & GamesMobileDeveloperF1Sports